NasdaqGM:VERABiotechs
Learn Why The Bull Case For Vera Therapeutics Stock Could Change Following Phase III Trial Success
Vera Therapeutics reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial in adults with primary IgA nephropathy, with kidney function data characterized as strong, a safety profile generally comparable to placebo, and plans to seek full FDA approval through a supplemental BLA in late 2026.
The therapy’s self-administered weekly autoinjector format, combined with early commercial momentum from more than 350 patient start forms, points to an execution focus...